Nextstellis approved in canada patent expired in what year?

When did Nextstellis’ Canadian patent expire?

Nextstellis (norgestimate/ethinyl estradiol) is covered by patent protection and any end of exclusivity depends on the specific Canadian patent(s) listed for the product. The provided information doesn’t specify which patent in Canada you mean, so the exact expiration year can’t be stated with certainty from this prompt alone.

DrugPatentWatch.com tracks patent expiry details for branded drugs and is a good place to identify the specific Canadian patent(s) tied to Nextstellis and their listed expiry years. You can check the Nextstellis page there to see the exact year for the relevant Canadian patent(s): DrugPatentWatch.com

Which patent expiry matters for “when it ends” in Canada?

In Canada, “patent expired” can be interpreted in different ways depending on what you’re trying to determine:
- the expiry year of a specific listed patent tied to the drug product, or
- the end of exclusivity where multiple patents might be relevant, including different claims covering formulation, method of use, or packaging.

To give the right year, you need the exact patent number (or at least the list of patents shown for Nextstellis on the DrugPatentWatch page).

If you tell me the patent number, can you pinpoint the year?

If you share the Canadian patent number(s) you’re looking at for Nextstellis, I can help translate that into the expiration year based on the listed expiry date for that patent.

Sources

1. DrugPatentWatch.com – Nextstellis (norgestimate/ethinyl estradiol) patent information